First Study Tests New Combo Tx for HCV/HIV Co-Infection
Researchers from the University of California, San Diego School of Medicine reported a new combination therapy that effectively treated hepatitis C virus (HCV) in patients co-infected with HIV. Findings from the study are published in the New England Journal of Medicine.
This was the first study to test the sofosbuvir/daclatasvir regimen in patients co-infected with HIV and HCV who had not received HCV treatment (n=151) and those who had been previously treated (n=52). Patients were randomized 2:1 to receive either 12 weeks or eight weeks of daclatasvir 60mg daily + sofosbuvir 400mg daily. The primary endpoint was sustained virologic response at Week 12 after the end of therapy among previously untreated patients with HCV genotype 1; patients were monitored up to 24 weeks post-treatment. Rates of sustained virologic response across genotypes 1–4 were 96.4% (95% CI: 89.8–99.2), 97% (95% CI: 91.6–99.4), 76.0% (95% CI: 61.8–86.9) , and 98.1% (95% CI: 89.7–100), respectively. Study authors also reported that HIV-1 suppression was compromised.
Sofosbuvir is an HCV NS5B polymerase inhibitor indicated as part of a combination antiviral treatment regimen for chronic hepatitis C (CHC) genotype 1, 2, 3, or 4 infection, including those with hepatocellular carcinoma meeting Milan criteria (awaiting liver transplant), and those with HCV/HIV-1 co-infection. Daclatasvir is an investigational NS5A replication complex inhibitor.
For more information visit Health.UCSD.edu.